These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34217228)

  • 1. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.
    Qvick A; Stenmark B; Carlsson J; Isaksson J; Karlsson C; Helenius G
    Mol Med; 2021 Jul; 27(1):68. PubMed ID: 34217228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
    Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
    Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
    Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
    Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
    Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
    Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I-IV Non-Small Cell Lung Cancer.
    Jiang J; Adams HP; Yao L; Yaung S; Lal P; Balasubramanyam A; Fuhlbrück F; Tikoo N; Lovejoy AF; Froehler S; Fang LT; Achenbach HJ; Floegel R; Krügel R; Palma JF
    J Mol Diagn; 2020 Feb; 22(2):228-235. PubMed ID: 31837429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay.
    Belloum Y; Janning M; Mohme M; Simon R; Kropidlowski J; Sartori A; Irwin D; Westphal M; Lamszus K; Loges S; Riethdorf S; Pantel K; Wikman H
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal Architecture of
    Ai X; Cui J; Zhang J; Chen R; Lin W; Xie C; Liu A; Zhang J; Yang W; Hu X; Hu X; Zhao Q; Rao C; Zang YS; Ning R; Li P; Chang L; Yi X; Lu S
    Clin Cancer Res; 2021 Feb; 27(3):704-712. PubMed ID: 33188140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.
    Satapathy S; Singh V; Nambirajan A; Malik PS; Tanwar P; Mehta A; Suryavanshi M; Thulkar S; Mohan A; Jain D
    Curr Probl Cancer; 2021 Dec; 45(6):100722. PubMed ID: 33712318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.